Background:
The roadmap concept suggests the use of ontreatment HBV DNA to guide treatment strategy of chronic hepatitis B patients treated by telbivudine. Our aim was to validate the roadmap approach of entecavir switch therapy in patients with incomplete response to telbivudine. Methods: Consecutive chronic hepatitis B patients on telbivudine monotherapy were studied. Incomplete virological response was defined as detectable HBV DNA after 6-12 months of treatment. Maintained virological response was defined as undetectable HBV DNA until the last follow-up. Results: Among the 79 patients on telbivudine, 39 (49%) had undetectable HBV DNA after 6-12 months of telbivudine treatment and 40 (51%) had incomplete virological response. In total, 33 incomplete responders switched to entecavir at 11 months (6-23), and 26 (79%) achieved maintained virological response after 25 months (4-46). Low HBV DNA level before switch therapy was the independent factor associated with maintained virological response to entecavir (P=0.01). A total of 24 of 25 (96%) patients with HBV DNA<2,000 IU/ml, versus 2 of 8 (25%) patients with HBV DNA≥2,000 IU/ml, had maintained virological response after switching to entecavir. Although rtM204I and/or rtL180M was detected in 3 of 7 patients with incomplete virological response to entecavir, none of the patients with HBV DNA<2,000 IU/ml during telbivudine treatment harboured these amino acid substitutions. Conclusions: Roadmap approach using entecavir switch at month 6-12 among incomplete responders to telbivudine is recommended if the HBV DNA is <2,000 IU/ml at the time of switching.
Chronic HBV infection affects approximately 400 million people worldwide, and three-quarters of them are from the Asia-Pacific region [1] [2] [3] . Complications, including liver cirrhosis, liver failure and hepatocellular carcinoma (HCC), occur in approximately one-quarter of them. Nucleoside/nucleotide analogue treatment can suppress viral replication, delay cirrhotic complications and reduce the risk of HCC [4, 5] . Entecavir and tenofovir are recommended as first-line therapy by all regional guidelines because of their high antiviral potency and low risk of inducing resistance, yet they are costly and may not be affordable in developing areas [6] [7] [8] . Telbivudine is another potent agent and is inexpensive in most Asian countries [9] . It has better HBV DNA suppression than lamivudine and adefovir dipivoxil after 52 weeks of treatment and is, thus, also endorsed by the Asian Pacific Association for the Study of the Liver as an acceptable first-line agent [8, [10] [11] [12] . A cost-effective analysis suggested one might start with lamivudine or telbivudine and switch to entecavir if HBV DNA is still detectable at week 24, which could be a cost-effective alternative to starting with entecavir monotherapy [13] . However, telbivudine resistance is an issue of concern. Previous studies reported telbivudine resistance occurred in 4.4% and 21% of hepatitis B e antigen (HBeAg)-positive patients and 2.7% and 8.6% of HBeAg-negative patients at 1 and 2 years of telbivudine treatment, respectively [11, 12] .
The GLOBE trial suggested that HBV DNA level at week 24 could predict telbivudine response and resistance [14] . If HBV DNA is still detectable at week 24, the risk of telbivudine resistance is considerable. Therefore, a group of international experts recommended the roadmap concept [15] . In patients with partial virological Introduction response (HBV DNA from 60 to 2,000 IU/ml) or inadequate response (HBV DNA≥2,000 IU/ml) at week 24, one should add a more potent drug with no crossresistance or switch to another drug with a high genetic barrier to resistance. However, the effectiveness of the roadmap approach has not been proven, and the optimal rescue therapy in patients with incomplete virological response remains undefined. Although current guidelines recommend adding or switching to another potent drug without cross-resistance in this context, the cost of this regimen is high in many countries [6] [7] [8] .
Entecavir monotherapy for chronic HBV infection is highly effective in both HBeAg-positive and -negative treatment-naive patients [16, 17] . The cumulative probability of genotypic entecavir resistance and virological breakthrough in nucleoside/nucleotide-naive patients was only 1.2% and 0.8%, respectively, over 5 years of entecavir treatment [18] .
In Hong Kong, chronic hepatitis B treatment is often paid by the patients. In many countries, entecavir is less expensive than tenofovir and adefovir, and the price difference will further increase because entecavir will go off-patent soon. Although there is a potential risk of cross-resistance between entecavir and telbivudine, the risk should be limited if rescue therapy is given promptly. Meanwhile, data on the efficacy of entecavir therapy on incomplete responders to telbivudine is lacking.
The aim of this study was to validate the roadmap concept by evaluating the efficacy of entecavir switch therapy in patients with incomplete response to telbivudine in a real-life cohort. Following this, we aimed to identify the factors that could predict favourable response to entecavir therapy in this setting.
Methods
This was a retrospective, prospective study. All chronic hepatitis B patients on telbivudine monotherapy who attended the Hepatitis Clinic of The Prince of Wales Hospital from 2003 to 2011 were identified by retrospective review of the case records. All patients had baseline HBV DNA level checked before treatment.
The inclusion criteria of the study were treatmentnaive patients with positive hepatitis B surface antigen (HBsAg) for 6 months or more, receiving telbivudine 600 mg daily. The exclusion criteria were previous or concurrent use of other antiviral treatment for chronic hepatitis B (including oral nucleoside/nucleotide analogues, interferon or pegylated interferon); patients with other liver diseases, such as chronic hepatitis C or autoimmune liver diseases; or coinfection with human immunodeficiency virus and pregnancy.
The clinical records of the patients were studied by two investigators (AO-SL and CM-TC). The medical and drug history was reviewed. Baseline and serial liver biochemistry, HBeAg, antibody against HBeAg (anti-HBe), HBsAg and HBV DNA level were recorded. Cirrhosis was defined by liver biopsy, radiographically with small liver and splenomegaly and/ or complications of cirrhosis, including presence of ascites or varices.
Antiviral treatment for chronic hepatitis B was initiated based on the liver function, viral load and presence of cirrhosis, according to the recommendations of international guidelines [6] [7] [8] . In brief, the patients had serum alanine aminotransferase (ALT) above the upper limit of normal and high HBV DNA level (over 20,000 IU/ml in HBeAg-positive patients and 2,000 IU/ml in HBeAg-negative patients) or cirrhosis with detectable HBV DNA. All patients on telbivudine had routine clinic follow-up in 3-6 months. Patients who had undetectable HBV DNA within 12 months were defined as initial responders. Patients who were on telbivudine monotherapy and had detectable HBV DNA at 6-12 months (defined as incomplete virological response) were recruited to a prospective study. Because most patients had to pay for antiviral drugs in Hong Kong, the choice of subsequent treatment for patients with incomplete virological response was a joint decision between the physician and patient. They were offered the options of continuing telbivudine or switching to entecavir 0.5 mg daily. Afterwards, the patients came back for 3-monthly follow-up, with liver biochemistry and alpha fetoprotein monitored at each visit. HBeAg, anti-HBe and HBV DNA were checked every 6 months, and HBsAg was checked yearly. In case of virological breakthrough, defined as an increase in HBV DNA for at least 1 log from the nadir, salvage therapy with adefovir dipivoxil or tenofovir was offered.
The primary efficacy end point was maintained virological response, defined as undetectable HBV DNA until the last follow-up. HBeAg seroconversion was defined as negative HBeAg and positive anti-HBe for at least two consecutive visits 6 months apart in patients with positive HBeAg before treatment. Other secondary end points included HBsAg seroclearance and normalization of ALT level. All patients in the prospective cohort provided informed written consent. The study protocol was approved by the Clinical Research Ethics Committee of The Chinese University of Hong Kong.
Laboratory tests
Enzyme-linked immunosorbent assay kits were used to test HBsAg (Roche Diagnostics Corp., Indianapolis, IN, USA), HBeAg and anti-HBe (Sanofi Diagnostics, Pasteur, France). TaqMan real-time PCR assay was used to measure HBV DNA [19] . The detection range was between 20 and 2×10 8 IU/ml.
Genotypic resistance analyses
Genotypic resistance was tested retrospectively in the stored serum samples of patients with detectable HBV DNA until the last visit or before switching to rescue therapy. A prototype line probe assay (LiPA) was used to detect HBV polymerase mutations associated with telbivudine, entecavir or adefovir (Inno-LiPA HBV DNA Multi-DR version 2 and 3 strips; LiPA Innogenetics, Ghent, Belgium). The lower limit of detection was 185 IU/ml.
Statistical analyses
Statistical analysis was performed using SPSS (version 18.0). Continuous variables were described as median (range) or mean ±sd, and compared using MannWhitney U test or Student's t-test as appropriate. Categorical parameters were compared using the c 2 test or Fisher's exact test. The factors associated with maintained virological response were analysed by Cox proportional hazard model. Cumulative probability was calculated by Kaplan-Meier method. In incomplete virological responders to telbivudine, the time-to-event curves in patient cohorts with entecavir therapy versus those with continued telbivudine were compared by log-rank test. Statistical significance was defined as P<0.05.
Results

Baseline characteristics and treatment response to telbivudine
A total of 106 chronic hepatitis B patients receiving telbivudine as first-line treatment from 2003 to 2011 were screened. After excluding treatment-experienced patients and those lost to follow-up, 79 patients were included for analysis (Figure 1 ). In total, 17 patients had telbivudine started in previous clinical trials [10] .
The majority of patients were males (Table 1 ). In total, 36 (46%) patients had an increased ALT level at baseline and 48% had cirrhosis. A total of 63 (80%) patients had baseline HBV DNA above 20,000 IU/ml. The median follow-up was 5.8 years (1.3-12) .
In total, 39 (49%) patients had initial response to telbivudine and achieved undetectable HBV DNA within the first 12 months of treatment (Figure 1 ). The cumulative probability of having undetectable HBV DNA at 1 and 2 years of telbivudine treatment was 50% and 57%, respectively. Of the 39 patients with initial virological response to telbivudine, 30 (77%) continued to have undetectable HBV DNA until the last visit at 5.8 years (1.6-8), 7 (18%) patients had virological breakthrough and 2 (5%) patients stopped telbivudine treatment and switched to herbal medicine. No patient achieved HBsAg seroclearance.
A total of 29 (37%) patients had positive HBeAg prior to antiviral treatment. In total, 12 (41%) had initial response to telbivudine with undetectable HBV DNA at 6-12 months. Among them, 7 achieved HBeAg seroconversion at a median of 12 months (3-73). The cumulative probability of HBeAg seroconversion at 1 and 2 years was 18% and 40%, respectively. In total, 27 of 50 patients (54%) with negative HBeAg before treatment had initial virological response and achieved undetectable HBV DNA at 6-12 months of telbivudine treatment.
The baseline characteristics were similar between initial responders to telbivudine and incomplete responders (Table 1) . Undetectable HBV DNA at 6-12 months of telbivudine treatment was the only factor associated with maintained virological response to telbivudine (P<0.01; Table 2 ). Among 40 (51%) patients with incomplete virological response at 6-12 months of telbivudine treatment, 33 patients switched to entecavir at 11 months (6-23), whereas 7 patients continued with telbivudine.
Response to entecavir in incomplete responders
In the entecavir group, 27/33 (82%) patients achieved undetectable HBV DNA after 7 months (3-18) of entecavir treatment. In total, 26 (79%) of them continued to have undetectable HBV DNA until the last visit at 25 months (4-46), but 1 of them developed virological breakthrough with an HBV DNA level of 3.2 log IU/ml at month 27 and adefovir was added. This patient could not achieve undetectable HBV DNA until the last visit at month 6 of combined entecavir and adefovir treatment (HBV DNA=5.5 log IU/ml). In total, 31 (94%) entecavirtreated patients had normal ALT at the last follow-up visit. None of the patients had HBsAg seroclearance.
A total of 6 patients failed to achieve undetectable HBV DNA after switching to entecavir therapy. The median HBV DNA level of these 6 patients was 4.5 log IU/ml (2.6-6.7) before entecavir treatment. One patient had ALT flare up to 239 IU/ml at month 23 of entecavir therapy, whereas the remaining 5 patients had normal ALT throughout the treatment period. In total 6 patients had positive HBeAg before switching to entecavir. One of them achieved HBeAg seroconversion with undetectable HBV DNA after 18 months of entecavir therapy.
Response to continuing telbivudine in incomplete responders
In total, 7 out of 40 patients (17%) continued with telbivudine therapy despite incomplete response to telbivudine with detectable HBV DNA within 12 months of initial treatment. None of them could achieve undetectable HBV DNA with additional telbivudine treatment for 32 months (13-39). Two patients received addon adefovir dipivoxil at months 22 and 32; 1 patient changed to tenofovir at month 39; 2 patients stopped telbivudine and switched to herbs at months 32 and 39; and 2 patients continued telbivudine monotherapy.
Among patients with incomplete virological response to telbivudine, the cumulative probability of maintained virological response among patients who received continued telbivudine was significantly lower than those who received entecavir rescue therapy (log-rank test P<0.001; Figure 2 ).
Genotypic mutations during telbivudine treatment
A total of 30 patients had maintained virological response with undetectable HBV DNA on telbivudine. The serum samples of the remaining 49 patients (40 with incomplete virological response and 9 had virological breakthrough) with detectable HBV DNA while on telbivudine treatment were retrieved for detection of genotypic resistance to antiviral drugs.
Amino acid substitutions at the reverse transcriptase were identified in 16 (20%) patients during telbivudine treatment at a median of 26 months (6-40; Table 3 ). Four patients simultaneously harboured rtL180M and rtM204I mutations, another 10 had single mutation of rtM204I. Three patients had rtA181T mutation at 6-17 months. The cumulative probability of amino acid substitution at years 1 and 2 was 6.0% and 18.6%, respectively.
The median level of HBV DNA at the time of identifying mutations was 4.6 log IU/ml (2.0-9.1). Among the 16 patients who developed amino acid substitutions at the reverse transcriptase, 12 (75%) had HBV DNA≥2,000 IU/ml (3.3 log IU/ml) when the amino acid substitution was first detected. The median ALT was 45 IU/ml (15-101) when the amino acid substitution was first noted; 4 of the 16 patients (25%) had ALT flare-up to 1.5-2× upper limit of normal.
In total, 7 out of 40 incomplete responders to telbivudine (18%) were found to have amino acid substitutions during telbivudine therapy. All of them had HBV DNA≥2,000 IU/ml when the amino acid substitutions were first detected; 5 of them switched to entecavir at a median of 14 months (6-23), and 3 of them failed to achieve undetectable HBV DNA with entecavir therapy.
Determinants of entecavir response
Among the 33 incomplete responders who switched from telbivudine to entecavir therapy, low HBV DNA level and absence of amino acid substitutions related to telbivudine resistance (rtM204I or rtL180M) before entecavir treatment were associated with maintained virological response to entecavir (Table 4) . On multivariate analysis by Cox proportional hazard model, low HBV DNA before switching to entecavir remained as an independent factor associated with maintained virological response, whereas rtM204I and/or rtL180M substitutions before entecavir showed a borderline significance. Maintained virological response after switching to entecavir (P<0.01) was achieved by 24 of 25 (96%) patients with HBV DNA<2,000 IU/ml versus 2 of 8 (25%) patients with HBV DNA≥2,000 IU/ml.
Amino acid substitutions contributing to potential entecavir resistance were found in 3 patients on entecavir therapy at 3-27 months, including 2 cases at rtT184 and 1 case at rtT184 and rtS202. All 3 patients had rtM204I during telbivudine treatment before switching to entecavir. The ALT levels of the 3 patients were normal when amino acid substitutions 
Discussion
The present study was a real-life cohort demonstrating the roadmap approach of telbivudine with entecavir switch for incomplete responders. Approximately half of the patients on telbivudine had incomplete HBV DNA suppression at months 6-12. After switching to entecavir, 79% and 94% of patients achieved undetectable HBV DNA and ALT normalization, respectively, at a median of 7 months. Low HBV DNA level before switching to entecavir could predict favourable response; 96% of patients could achieve undetectable HBV DNA with entecavir therapy if the HBV DNA was <2,000 IU/ml at the time of switching.
At the time when the roadmap approach was proposed, whether one should switch or add on another drug for the partial or inadequate responders was largely based on expert opinion [15] . In this study, we have demonstrated that switching to entecavir is a feasible strategy among patients who have HBV DNA <2,000 IU/ml. However, the response to entecavir might not be satisfactory among those with higher HBV DNA levels. A recent study reported the results of a roadmap approach using tenofovir add-on therapy among patients who had detectable HBV DNA at month 6 of telbivudine treatment. Among the 100 HBeAg-positive patients receiving telbivudine, 45 patients required addon tenofovir at month 6. At the end of 2 years, 94% patients had undetectable HBV DNA, 39% had HBeAg seroconversion and 7% had HBsAg seroclearance [20] . Although effective, dual therapy with tenofovir and telbivudine is costly and may not be affordable by most patients in developing countries. Up to date, there is no data on the roadmap approach for telbivudine using tenofovir switch (instead of add-on) for the incomplete responders at month 6.
Telbivudine belongs to the l-nucleoside family, which shares a similar structure to lamivudine. Resistance to telbivudine and lamivudine is mediated by the amino acid substitutions at rtM204I/V and rtA181T/V [21] . Amino acid substitution at rtL180M is a compensatory mechanism that will enhance the replicative efficacy of the HBV mutant with rtM204V/I. The development of entecavir resistance requires the presence of three amino acid substitutions, namely rtL180M, rtM204I/V and one or more substitutions at rt184, rt202 or rt250 [22, 23] . As a result of the partial cross-resistance between entecavir and lamivudine, the efficacy of entecavir is decreased in the presence of lamivudine resistance. The risk of entecavir resistance and virological breakthrough among patients with lamivudine resistance could be as high as 51% and 43% at 5 years, respectively [18] . One important finding of this study was the early development of amino acid mutations at as early as month 6 of telbivudine treatment. Three patients developed amino acid substitutions within the first year, including one case of rtM204I and rtA181T mutations simultaneously at month 6 (patient number 10), one case of rtM204I mutation at month 11 (patient number 11) and one case of rtA181T mutation at month 7 (patient number 15) .
This study demonstrated that the presence of amino acid mutations in telbivudine-treated patients could adversely affect the efficacy of subsequent entecavir therapy. In our cohort, 14 (18%) patients harboured rtM204I ± rtL180M after 26 months (6-40) of telbuvidine treatment. Moreover, rtA181T mutation was identified in three patients on telbivudine treatment. An amino acid substitution at position rt181 may also decrease susceptibility to tenofovir treatment but remain sensitive to entecavir [24, 25] . However, patient number 16 who developed only rtA181T mutation at month 7 with high HBV DNA (5.3 log IU/ml) failed to achieve undetectable HBV DNA after switching to entecavir therapy for 32 months (Table 3) . Therefore, in telbivudine-treated patients with incomplete virological response, resistance testing is recommended, particularly among those with HBV DNA>2,000 IU/ml. Knowing the presence of amino acid mutations before switching therapy will assist the proper choice of antiviral drug to avoid crossresistance in subsequent treatment [26] . Tenofovir may be a better alternative to entecavir if rtM204I and/or rtL180M were present.
This study has highlighted the practicability of the roadmap approach in clinical practice. In Hong Kong, because most antiviral drugs were self-financed items during the study period, some patients would prefer telbivudine as the initial regime as a result of its affordability. Besides, tenofovir was more costly than entecavir in Hong Kong. Therefore, the initiation of entecavir in incomplete responders to telbivudine was largely influenced by affordability and preference of the patients. Many a time, after being notified of having detectable HBV DNA at month 6, patients requested extra time to consider the treatment options and could only make a decision in a subsequent follow-up visit. The delay of switching therapy among incomplete responders inevitably increased the risk of telbivudine resistance, hence decreased the chance of success in subsequent treatment. Some patients decided to switch to alternative medicine when they had suboptimal treatment response with antiviral treatment. An example was patient number 1, who was an initial responder to telbivudine and developed virological breakthrough at month 31 (Table 3) . He declined further antiviral treatment and switched to herbal medicine until month 70, when he agreed to receive entecavir therapy. The heterogeneity of timing and options of switching therapy reflected the difficulty to strictly follow the roadmap approach in real-life clinical setting.
Our study had a few limitations. The retrospective nature of data retrieval might introduce bias and incomplete data collection. Fortunately, chronic hepatitis B patients attending our clinic had regular 3-to 6-monthly follow-up with blood tests at each visit. HBV DNA levels were checked in regular 6-month intervals. There was no missing data regarding the HBV DNA levels in our study. The second limitation was the relatively small sample size in this single-centre study. We tried to overcome this limitation by recruiting patients over an 8-year period.
In conclusion, switching to entecavir therapy could achieve undetectable HBV DNA in approximately 80% of patients with incomplete virological response to telbivudine. High HBV DNA level and presence of amino acid substitutions before switching therapy were associated with failure of subsequent entecavir treatment.
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